Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Healthcare

Telix Pharmaceuticals (ASX:TLX): What Do Q3 Revenue Growth and New Imaging Milestones Mean for 2026?

Telix Pharmaceuticals (ASX:TLX) operates across Precision Medicine, Therapeutics and Telix Manufacturing Solutions (TMS). Precision Medicine markets molecular imaging products that help clinicians identify or assess cancer. Illuccix and Gozellix are gallium-68-labelled prostate-specific membrane antigen imaging products used in positron emission tomography (PET). The division …

Aditi Sarkar | 27 October 2026

EBOS Group Limited (ASX:EBO): What Do FY26 Earnings and Distribution Centre Investments Reveal?

EBOS Group Limited (ASX:EBO) operates through Healthcare and Animal Care segments. Healthcare encompasses Symbion and other medicines distribution operations, contract logistics, hospital and medical consumables supply, pharmacy banner services and specialist medical technology. Its activities extend across Australia, New Zealand, Southeast Asia and Hong …

Aditi Sarkar | 27 October 2026

Mesoblast Limited (ASX:MSB): What Do RYONCIL Sales and Clinical Milestones Mean for FY27?

Mesoblast Limited (ASX:MSB) specialises in allogeneic cellular therapies, using donor-derived cells manufactured for potential use across multiple patients. This model differs from therapies individually produced from a patient’s own cells. The company must coordinate cell sourcing, consistent manufacturing processes, regulatory release testing and distribution …

Aditi Sarkar | 27 October 2026

Neuren Pharmaceuticals (ASX:NEU): How Are DAYBUE Royalties Funding Clinical Development?

Neuren Pharmaceuticals Limited (ASX:NEU) develops treatments for serious neurological conditions, with royalty income from its licensed Rett syndrome therapy supporting research on additional disorders. The shares were quoted at AUD 18.70 in the 27 October 2026 price information, while Neuren’s H1 2026 results showed …

Aditi Sarkar | 27 October 2026

4DMedical Limited (ASX:4DX): What Do FY26 Scan Volumes and CT:VQ Rollout Reveal?

4DMedical Limited (ASX:4DX) supplies imaging analysis tools to hospitals, radiology providers and other healthcare customers. Its software portfolio includes CT:VQ, which assesses regional lung ventilation and perfusion from CT imaging without injected contrast, along with lung volume, lung density and other analytical applications. The …

Aditi Sarkar | 27 October 2026

PYC Therapeutics (ASX:PYC): What Do Its 2026 Clinical Milestones Mean for the Drug Pipeline?

PYC Therapeutics Limited (ASX:PYC) develops investigational RNA-based medicines aimed at inherited disorders affecting the eyes, kidneys and central nervous system. Its shares were quoted at AUD 1.92 on 27 October 2026, while recent company disclosures focused on clinical testing of PYC-003 for polycystic kidney …

Aditi Sarkar | 27 October 2026

Ryman Healthcare (ASX:RYM): What Does the Eight-Quarter High in Resales Mean for FY27?

Ryman Healthcare Limited (ASX:RYM) operates integrated villages offering independent retirement living, serviced apartments and aged care within the same communities. The model combines occupation right agreement sales with care and village fees, deferred management fees and other resident-related revenue. Its activities span New Zealand …

Aditi Sarkar | 27 October 2026

Regis Healthcare Limited (ASX:REG): What Do FY26 Results Reveal About Occupancy and Aged Care Expansion?

Regis Healthcare Limited (ASX:REG) operates residential aged care homes in Australia and also provides home care, respite, day therapy and retirement living services. Its revenue depends on resident care funding, accommodation arrangements and fees for services. The business operates under national aged care standards, …

Aditi Sarkar | 27 October 2026

Summerset Group Holdings (ASX:SNZ): Why Did Underlying Profit Ease Despite Higher Half-Year Sales?

Summerset Group Holdings (ASX:SNZ) develops retirement living accommodation, sells occupation-right agreements (ORAs) and operates care services within its villages. The business maintains an established New Zealand portfolio and has expanded its Australian development presence, where project completion and settlement schedules influence reported results.

Aditi Sarkar | 27 October 2026

Nanosonics Limited (ASX:NAN): How Will CORIS Commercialisation Follow FY26 Revenue Growth?

Nanosonics Limited (ASX:NAN) sells automated high-level disinfection systems, related consumables and support services to healthcare providers. Its principal product family, trophon, reprocesses ultrasound probes between patient procedures. Device sales build an installed fleet that generates subsequent consumables and servicing revenue, making adoption, usage and …

Aditi Sarkar | 27 October 2026
Support

Hi! How can we help you today?

Loading…